Clinical trials
Phase 1 Lymphoma trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 55 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beijing Doing Biomedical Co., Ltd. | 3 |
| iCell Gene Therapeutics | 3 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Milton S. Hershey Medical Center | 2 |
| University of California, Davis | 2 |
| Anwita Biosciences | 1 |
| Armando Santoro, MD | 1 |
| BJ Bioscience, Inc. | 1 |
| Cancer Research UK | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma | 55 |
| Leukemia | 13 |
| Lymphoma, Non-Hodgkin | 10 |
| Lymphoma, Follicular | 9 |
| Lymphoma, Large B-Cell, Diffuse | 9 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 |
| Burkitt Lymphoma | 8 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Lymphoma, Large-Cell, Immunoblastic | 8 |
| Hodgkin Disease | 7 |
Trials
Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.